http://www.medscape.com/viewarticle/845008
Ozanimod, a novel sphingosine 1-phosphate receptor modulator, is safe and effective in the treatment of patients with moderate to severe ulcerative colitis, according to results from the phase 2 TOUCHSTONE study.
"Ozanimod 1 mg induced clinical remission at week 8, the primary end point, and met all three secondary end points," said William Sandborn, MD, from the University of California, San Diego.
"And the favorable benefit–risk profile supports the planned phase 3 trial and the phase 2 study in Crohn's disease," he reported here at Digestive Disease Week 2015.
Anyone understands how this drug is different from immuno-supressor or Biologics and if it appears less invasive?
Ozanimod, a novel sphingosine 1-phosphate receptor modulator, is safe and effective in the treatment of patients with moderate to severe ulcerative colitis, according to results from the phase 2 TOUCHSTONE study.
"Ozanimod 1 mg induced clinical remission at week 8, the primary end point, and met all three secondary end points," said William Sandborn, MD, from the University of California, San Diego.
"And the favorable benefit–risk profile supports the planned phase 3 trial and the phase 2 study in Crohn's disease," he reported here at Digestive Disease Week 2015.
Anyone understands how this drug is different from immuno-supressor or Biologics and if it appears less invasive?
